ABSTRACT
The objective of this study was to investigate the risk of attenuated efficacy due to adaptive resistance for the siderophore-conjugated monocarbam SMC-3176 in Pseudomonas aeruginosa by using a pharmacokinetic/pharmacodynamic (PK/PD) approach. MICs were determined in cation-adjusted Mueller-Hinton broth (MHB) and in Chelex-treated, dialyzed MHB (CDMHB). Spontaneous resistance was assessed at 2× to 16× the MIC and the resulting mutants sequenced. Efficacy was evaluated in a neutropenic mouse thigh model at 3.13 to 400 mg/kg of body weight every 3 h for 24 h and analyzed for association with free time above the MIC (fT>MIC). To closer emulate the conditions of the in vivo model, we developed a novel assay testing activity mouse whole blood (WB). All mutations were found in genes related to iron uptake: piuA, piuC, pirR, fecI, and pvdS. Against four P. aeruginosa isolates, SMC-3176 displayed predictable efficacy corresponding to the fT>MIC using the MIC in CDMHB (R(2) = 0.968 to 0.985), with stasis to 2-log kill achieved at 59.4 to 81.1%. Efficacy did not translate for P. aeruginosa isolate JJ 4-36, as the in vivo responses were inconsistent with fT>MIC exposures and implied a threshold concentration that was greater than the MIC. The results of the mouse WB assay indicated that efficacy was not predictable using the MIC for JJ 4-36 and four additional isolates, against which in vivo failures of another siderophore-conjugated ß-lactam were previously reported. SMC-3176 carries a risk of attenuated efficacy in P. aeruginosa due to rapid adaptive resistance preventing entry via the siderophore-mediated iron uptake systems. Substantial in vivo testing is warranted for compounds using the siderophore approach to thoroughly screen for this in vitro-in vivo disconnect in P. aeruginosa.
Subject(s)
Anti-Bacterial Agents/pharmacology , Azetidines/pharmacology , Drug Resistance, Bacterial/genetics , Pseudomonas aeruginosa/metabolism , Siderophores/pharmacology , Sulfonamides/pharmacology , Animals , Anti-Bacterial Agents/pharmacokinetics , Azetidines/pharmacokinetics , Female , Iron/metabolism , Mice , Mice, Inbred ICR , Microbial Sensitivity Tests , Oligopeptides/metabolism , Pseudomonas Infections/drug therapy , Pseudomonas Infections/microbiology , Pseudomonas aeruginosa/drug effects , Siderophores/pharmacokinetics , Sulfonamides/pharmacokinetics , beta-Lactamases/metabolismABSTRACT
Respiratory syncytial virus (RSV) drug discovery has been hindered by the lack of good chemistry starting points and would benefit from robust and convenient assays for high-throughput screening (HTS). In this paper, we present the development and optimization of a 384-well RSV replicon assay that enabled HTS for RSV replication inhibitors with a low bio-containment requirement. The established replicon assay was successfully implemented for high-throughput screening. A validation screen was performed which demonstrated high assay performance and reproducibility. Assay quality was further confirmed via demonstration of appropriate pharmacology for different classes of RSV replication tool inhibitors. RSV replicon and cytotoxicity assays were further developed into a multiplexed format that measured both inhibition of viral replication and cytotoxicity from the same well. This provided a time and cost efficient approach to support lead optimization. In summary, we have developed a robust RSV replicon assay to help expedite the discovery of novel RSV therapeutics.
Subject(s)
Antiviral Agents/isolation & purification , Drug Evaluation, Preclinical/methods , Respiratory Syncytial Viruses/drug effects , Respiratory Syncytial Viruses/physiology , Virus Replication/drug effects , Antiviral Agents/pharmacology , Antiviral Agents/toxicity , Cell Survival/drug effects , Containment of Biohazards/methods , High-Throughput Screening Assays , Humans , Replicon , Reproducibility of Results , Respiratory Syncytial Viruses/geneticsABSTRACT
UMP kinase (PyrH) is an essential enzyme found only in bacteria, making it ideal as a target for the discovery of antibacterials. To identify inhibitors of PyrH, an assay employing Staphylococcus aureus PyrH coupled to pyruvate kinase/lactate dehydrogenase was developed and was used to perform a high throughput screen. A validated aminopyrimidine series was identified from screening. Kinetic characterization of this aminopyrimidine indicated it was a competitive inhibitor of ATP. We have shown that HTS can be used to identify potential leads for this novel target, the first ATP competitive inhibitor of PyrH reported.
Subject(s)
Adenosine Triphosphate/pharmacology , Enzyme Inhibitors/pharmacology , Nucleoside-Phosphate Kinase/antagonists & inhibitors , Staphylococcus aureus/drug effects , Staphylococcus aureus/enzymology , Drug Evaluation, Preclinical , Enzyme Assays , Enzyme Inhibitors/chemistry , High-Throughput Screening Assays , Kinetics , Microbial Sensitivity Tests , Nucleoside-Phosphate Kinase/metabolism , Pyrimidines/chemistry , Pyrimidines/pharmacology , Reproducibility of ResultsABSTRACT
A successful scaffold-hopping approach gave a novel series of inhibitors of bacterial glutamate racemase (MurI). Early SAR studies of the 8-benzyl pteridine-6,7-diones led to compounds with micromolar enzyme potency and antibacterial activity.
Subject(s)
Amino Acid Isomerases/antagonists & inhibitors , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/pharmacology , Gram-Positive Bacteria/enzymology , Pteridines/chemical synthesis , Pteridines/pharmacology , Anti-Bacterial Agents/chemistry , Combinatorial Chemistry Techniques , Gram-Positive Bacteria/drug effects , Microbial Sensitivity Tests , Molecular Structure , Pteridines/chemistry , Structure-Activity RelationshipABSTRACT
An early SAR study of a screening hit series has generated a series of 9-benzyl purines as inhibitors of bacterial glutamate racemase (MurI) with micromolar enzyme potency and improved physical properties. X-ray co-crystal EI structures were obtained.
Subject(s)
Amino Acid Isomerases/antagonists & inhibitors , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/pharmacology , Gram-Positive Bacteria/enzymology , Purines/chemical synthesis , Purines/pharmacology , Anti-Bacterial Agents/chemistry , Combinatorial Chemistry Techniques , Crystallography, X-Ray , Enterococcus faecalis/drug effects , Enterococcus faecalis/genetics , Enterococcus faecium/drug effects , Enterococcus faecium/genetics , Gram-Positive Bacteria/genetics , Molecular Conformation , Molecular Structure , Purines/chemistry , Staphylococcus aureus/drug effects , Staphylococcus aureus/genetics , Structure-Activity RelationshipABSTRACT
The PDE4 catalytic machinery comprises, in part, two divalent cations in a binuclear motif. Here we report that PDE4A4 expressed in Sf9 cells exhibits a biphasic Mg(2+) dose-response (EC(50) of 0.15 and >10 mM) in catalyzing cAMP hydrolysis. In vitro phosphorylation of PDE4A4 by the PKA-catalytic subunit increases the enzyme's sensitivity to Mg(2+), leading to 4-fold increased cAMP hydrolysis without affecting its K(m). The phosphorylation also increases the potencies of (R)- and (S)-rolipram without affecting CDP-840 and SB-207499. The results support that modulating the cofactor binding affinity of PDE4 represents a mechanism for regulating its activity.